This site is intended for healthcare professionals

Lynparza reduced the risk of death by 31% in BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer in phase III PROfound trial. AstraZeneca + Merck Inc.

Read time: 1 mins
Last updated:21th Sep 2020
Published:21th Sep 2020
Condition: Prostate Cancer
Type: drug
Register free for full access to